Edition:
United States

Tocagen Inc (TOCA.OQ)

TOCA.OQ on NASDAQ Stock Exchange Global Select Market

9.38USD
20 Jul 2018
Change (% chg)

$0.18 (+1.96%)
Prev Close
$9.20
Open
$9.25
Day's High
$9.38
Day's Low
$9.07
Volume
18,787
Avg. Vol
33,630
52-wk High
$14.49
52-wk Low
$8.32

Chart for

About

Tocagen Inc. (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to... (more)

Overall

Beta: --
Market Cap(Mil.): $183.20
Shares Outstanding(Mil.): 19.91
Dividend: --
Yield (%): --

Financials

  TOCA.OQ Industry Sector
P/E (TTM): -- 217.69 33.34
EPS (TTM): -2.25 -- --
ROI: -106.77 -3.65 13.18
ROE: -- -5.62 15.09

BRIEF-Tocagen Entered Amended And Restated Loan And Security Agreement For $26.5 Mln

* TOCAGEN - ENTERED AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT FOR $26.5 MILLION AS TERM LOANS FUNDED ON EFFECTIVE DATE - SEC FILING Source text: (https://bit.ly/2IEQjX8) Further company coverage:

May 23 2018

BRIEF-Tocagen Reports Q1 Loss Per Share $0.65

* TOCAGEN REPORTS FIRST QUARTER 2018 FINANCIAL AND BUSINESS RESULTS

May 10 2018

BRIEF-Tocagen And ApolloBio Enter License Agreement To Develop Toca 511 & Toca FC In Greater China

* TOCAGEN AND APOLLOBIO ENTER LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE TOCA 511 & TOCA FC IN THE GREATER CHINA REGION

Apr 19 2018

BRIEF-Tocagen Q4 Loss Per Share $0.55

* TOCAGEN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL AND BUSINESS RESULTS

Mar 08 2018

BRIEF-Tocagen Receives EMA Orphan Medicinal Product Designation For Toca 511 & Toca FC For Glioma Treatment

* TOCAGEN RECEIVES EUROPEAN MEDICINES AGENCY ORPHAN MEDICINAL PRODUCT DESIGNATION FOR TOCA 511 & TOCA FC FOR THE TREATMENT OF GLIOMA Source text for Eikon: Further company coverage:

Mar 07 2018

Earnings vs. Estimates